First Trust Bank Ltd. Makes New $1.62 Million Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

First Trust Bank Ltd. bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 3,054 shares of the medical research company’s stock, valued at approximately $1,621,000. Thermo Fisher Scientific accounts for approximately 2.2% of First Trust Bank Ltd.’s investment portfolio, making the stock its 14th biggest position.

A number of other large investors have also added to or reduced their stakes in the company. Northwest Financial Advisors acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Raleigh Capital Management Inc. increased its stake in Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after acquiring an additional 27 shares during the last quarter. Cedar Mountain Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after buying an additional 46 shares during the period. Frazier Financial Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth $49,000. Finally, Pacific Capital Wealth Advisors Inc. purchased a new position in Thermo Fisher Scientific in the fourth quarter valued at $51,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $0.98 during trading on Friday, hitting $584.05. 883,091 shares of the stock were exchanged, compared to its average volume of 1,501,020. The company has a fifty day moving average price of $576.44 and a two-hundred day moving average price of $545.98. The company has a market cap of $222.94 billion, a PE ratio of 37.34, a P/E/G ratio of 2.76 and a beta of 0.80. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be given a $0.39 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent research reports. Barclays lifted their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday, April 25th. Evercore ISI lifted their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Royal Bank of Canada lifted their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $607.35.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,873,516.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,000 shares of company stock worth $18,486,980. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.